Zain Rizvi

Research Director


Zain Rizvi is an expert on pharmaceutical innovation and access to medicines. He has provided technical assistance to governments, investigated public rights in taxpayer-funded technologies, and analyzed neglected legal authorities to increase access to medicines.

During the coronavirus pandemic, he mapped distinct sources of the U.S. government’s legal authority to share vaccine technology. He also worked with journalists to uncover a major patent inventorship dispute between the National Institutes of Health and Moderna; with process engineers to model the resources required to produce enough coronavirus vaccine for the world; and with epidemiologists to estimate the number of lives that could be saved through global vaccination. His analysis helped yield new U.S. commitments to share coronavirus vaccine doses and technology.

Zain’s work has been published in medical and legal journals, including The Lancet and the Yale Journal of Law & Technology. He was previously a Gruber Fellow at SECTION27, a Johannesburg-based public interest organization. A member of the D.C. bar, Zain obtained a J.D. from Yale Law School, where he was student director of the Yale Global Health Justice Partnership.

Media Appearances

Zain has been quoted in The New York Times, The Washington Post, The Wall Street Journal, The Financial Times, and The Associated Press. He has appeared on MSNBC, NPR, and PBS, in addition to the ABC (Australia), BBC (U.K.), CTV (Canada), NBS TV (Uganda), RAI (Italy), SABC (South Africa), and SBS (South Korea).